Abstract
Associations of polymorphisms of genes FGB G(−455)A and PROC C(−1654)T with the frequency of poor outcomes in patients with the history of acute coronary syndrome (ACS) were studied in the Russian population. A total of 1145 patients admitted to cardiological hospitals of Moscow, St. Petersburg, Kazan, Chelyabinsk, Perm, Stavropol, and Rostov-on-Don with ischemic heart disease exacerbation were examined. The mean follow-up time was 1.14 ± 0.33 years, and the maximum follow-up time was 3.2 years. The risk of poor outcome did not depend on the carriership of genotypes of the polymorphic G(−455)A marker in the FGB gene. However, the PROC C(−1654)T polymorphism patients with ACS history and allele T of the PROC gene had a poor outcome more often than patients homozygous for allele C. The survival time to the endpoint for carriers of the TT and CT genotypes of the PROC gene was 2.19 ± 0.18 years vs. 2.46 ± 0.16 years for carriers of the CC genotype. On the base of these results it is suggested that hemostasis-related genes play an important role in early failures in patients with ACS history.
Similar content being viewed by others
Abbreviations
- IHD:
-
ischemic heart disease
- MI:
-
myocardial infarction
- LDL:
-
low-density lipoproteins
- ACS:
-
acute coronary syndrome
- CVD:
-
cardiovascular diseases
- FGB:
-
gene coding β-chain of fibrinogen
- PROC:
-
gene coding protein C.
References
Oganov R.G., Maslennikova G.Ya. 2003. Impact of cardiovascular and other noninfectious diseases on population health in Russia. Serdtse. 2, 58–61.
Shevchenko O.P., Mishnev O.D. 2005. Ishemicheskaya bolezn’ serdtsa (Ischemic Heard Disease), Moscow: Reafarm.
Goyal A., Blazing M. 2005. Should we measure C-reactive protein levels to ascertain the adequacy of statin therapy in patients who are at very high risk for a coronary heart disease event? Am. Heart J. 150, 650–651.
Aronov D.A. 2002. Primary and secondary prophylaxis of cardiovascular diseases: Interpolation to Russia. Serdtse. 3, 109–112.
Pratt R.E., Dzau V.J. 1999. Genomics and hypertension: Concepts, potentials, and opportunities. Hypertension. 33, 238–247.
Damani M.D., Topol M.D. 2007. Future use of genomics in coronary artery disease. J. Am. Coll. Cardiol. 50, 1933–1940.
Meade T.W., Mellows S., Brozovic M., et. al. 1986. Haemostatic function and ischemic heart disease: Principal results of the Horthwick Park Heart Stydy. Lancet. 2, 533–537.
van’t Hooft F.M., von Bahr S.J. 1999. Two common, functional polymorphisms in the promoter region of the beta-fibrinogen gene contribute to regulation of plasma fibrinogen concentration. Arterioscler. Thromb. Vasc. Biol. 19, 3063–3070.
Spek C.A., Koster T., Rosendaal F.R., et al. 1995. Genotypic variation in the promoter region of the protein C gene is associated with plasma protein C levels and thrombotic risk. Arterioscler. Thromb. Vasc. Biol. 15, 214–218.
Bogaty P., Robitaille N.-M., Solymoss S., et al. 1998. Atherogenic, hemostatic, and other potential risk markers in subjects with previous isolated myocardial infarction compared with long-standing uncomplicated stable angina. Am. Heart J. 136, 884–893.
Mathew C.G.P. 1984. The isolation of high molecular weight eukaryotic DNA. Methods Mol. Biol. 2, 31–34.
Green F., Hamster A., Blomback M., Humphries S. 1993. The role of beta-fobrinogen genotype in determining plasma fibrinogen levels in young survivors of myocardial infarction and healthy controls from Sweden. Thromb. Haemost. 70, 915–920.
Folsom A.R., Aleksic N., Ahn C., et al. 2001. Betafibrinogen gene −455G/A polymorphism and coronary heart disease incidence: The atherosclerosis risk in communities (ARIC) study. Ann. Epidemiol. 11, 166–170.
Zee R.Y., Diehl K.A., Ridker P.M. 2005. Complement factor H Y402H gene polymorphism, C-reactive protein, and risk of incident myocardial infarction, ischaemic stroke, and venous thromboembolism: A nested case-control study. Atherosclerosis. 60, 126–136.
Sampaio M.F., Hirata M.H., Crespo H., et al. 2007. AMI is associated with polymorphisms in the NOS3 and FGB but not in PAI-1 genes in young adults. Clin. Chim. Acta. 377, 154–162.
Chudakova D.A., Minushkina L.O., Zateyshchikov D.A., Nosikov V.V. 2004. Association of polymorphic marker A1/A2 of gene ITGB3 with coronary artery disease and myocardial infarction. Genetika. 40, 1406–1409.
Tybjaerg-Hansen A., Agerholm-Larsen B., Humphries S.E., Abildgaard S., Schnohr P., Nordestgaard B.G. 1997. A common mutation (G −455 → A) in the betafibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9127 individuals based on the Copenhagen City Heart Study. J. Clin. Invest. 99, 3034–3039.
Doggen C., Bertina R. 2000. Fibrinogen polymorphisms are not associated with the risk of myocardial infarction. Br. J. Haematol. 110, 935–943.
Zakirova V.B., Brovkin A.N., Galeeva Z.M., et al. 2008. Genetic predisposition to unfavorable course of ischemic heart disease in patients after acute coronary syndrom. Kardiologiya. 200, 13–18.
Martiskainen M., Pohjasvaara T., Mikkelsson J., et al. 2003. Fibrinogen gene promoter −455 A allele as a risk factor for lacunar stroke. Stroke. 34, 886–891.
Parfenov M.G., Titov B.V., Sudomoina M.A., Martynov M.Yu., Favorov A.V., Ochs M.F., Gusev E.I., Favorova O.O. 2009. Genetic susceptibility to ischemic stroke in Russians. Mol. Biol. 43, 873–880.
Hoth T., Evans T.W. 2001. Activated protein C: The cure for sepsis — again? Anaesthesia. 56, 1133–1135.
Sidorkina A.N., Sidorkin V.G., Presnyakova M.V. 2001. Biokhimicheskie osnovy gemostaza i disseminirovannoe vnutrisosudistoe svertyvanie krovi (Biochemical Bases of Homeostasis and Disseminated Intravascular Blood Coagulation), Novgorod: NNIITO.
Aiach M., Nicaud V., Gelas M.A., et al. 1999. Complex association of protein C gene promoter polymorphism with circulating protein C levels and thrombotic risk. Arterioscler. Thromb. Vasc. Biol. 19, 1573–1576.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © Yu.V. Agapkina, A.G. Nikitin, A.N. Brovkin, A.A. Pushkov, M.A. Evdokimova, O.Yu. Aseycheva, V.S. Osmolovskaya, L.O. Minushkina, M.S. Kochkina, N.D. Selezneva, E.N. Dankovtseva, O.S. Chumakova, T.N. Baklanova, P.A. Talyzin, N.E. Reznichenko, O.P. Donetskaya, S.N. Tereschenko, E.S. Krasil’nikova, N.A. Dzhaiani, E.V. Akatova, M.G. Glezer, A.S. Galyavich, V.B. Zakirova, N.A. Koziolova, I.V. Timofeeva, A.V. Yagoda, O.I. Boyeva, L.I. Katelnitskaya, E.V. Horolets, S.V. Shlyk, E.G. Volkova, M.P. Margaryan, I.O. Guz, V.O. Konstantinov, A.N. Timofeyeva, B.A. Sidorenko, D.A. Zateyshchikov, V.V. Nosikov, 2010, published in Molekulyarnaya Biologiya, 2010, Vol. 44, No. 4, pp. 613–619.
Rights and permissions
About this article
Cite this article
Agapkina, Y.V., Nikitin, A.G., Brovkin, A.N. et al. Association of the polymorphic markers G(−455)A in the FGB gene and C(−1654)T in the PROC gene with hereditary predisposition to unfavourable outcome in patients with history of acute coronary syndrome. Mol Biol 44, 541–545 (2010). https://doi.org/10.1134/S0026893310040060
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S0026893310040060